A Phase II, Multicenter Induction Study With an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients With Moderate to Severe Ulcerative Colitis
Latest Information Update: 30 Apr 2025
At a glance
- Drugs Vixarelimab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Genentech
Most Recent Events
- 04 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 11 Mar 2025 Planned End Date changed from 28 Feb 2027 to 29 Feb 2028.
- 11 Mar 2025 Planned primary completion date changed from 31 May 2026 to 22 Sep 2026.